PRKAA1 and Mitochondrial myopathy: Treatment with the AMPK agonist also elevated mitochondrial membrane potential in cell lines derived from patients suffering from Polɣ‐associated mitochondrial myopathy, but then through an mtDNA‐independent mechanism.